KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Raw Materials (2016 - 2024)

Nektar Therapeutics (NKTR) has 13 years of Raw Materials data on record, last reported at $1.7 million in Q2 2024.

  • For Q2 2024, Raw Materials changed N/A year-over-year to $1.7 million; the TTM value through Jun 2024 reached $1.7 million, changed N/A, while the annual FY2023 figure was $1.9 million, 27.73% down from the prior year.
  • Raw Materials reached $1.7 million in Q2 2024 per NKTR's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Raw Materials topped out at $2.6 million in Q4 2022 and bottomed at $1.7 million in Q2 2024.
  • Average Raw Materials over 3 years is $2.0 million, with a median of $1.9 million recorded in 2023.
  • The widest YoY moves for Raw Materials: up 27.73% in 2023, down 27.73% in 2023.
  • A 3-year view of Raw Materials shows it stood at $2.6 million in 2022, then fell by 27.73% to $1.9 million in 2023, then fell by 7.63% to $1.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $1.7 million in Q2 2024, $1.9 million in Q1 2024, and $1.9 million in Q4 2023.